Drug intelligence / Profile preview

BTL-203

Development stage: Unknown
Lead developer: Biotle
Modality: Peptides
Administration: Subcutaneous

Overview

BTL-203 is a long-acting tri-agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. Developed by Bendao Biotechnology (Hangzhou) Co., Ltd., it is designed for the treatment of metabolic disorders such as obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). By simultaneously activating these three pathways, BTL-203 aims to provide potent weight loss and glycemic control while also improving lipid metabolism and liver health. The drug is currently in Phase 1 clinical development, with studies evaluating its safety, tolerability, and pharmacokinetics in healthy participants.

Targets

FCGRT (Neonatal crystallizable fragment receptor)

Beyond the preview

Go deeper on BTL-203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BTL-203.

Explore the full profile